- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
- Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
On Thursday, Summit Therapeutics Inc (SMMT:NMQ) closed at 3.55, -31.99% below its 52-week high of 5.22, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.52 |
---|---|
High | 3.62 |
Low | 3.44 |
Bid | 3.51 |
Offer | 3.65 |
Previous close | 3.59 |
Average volume | 1.35m |
---|---|
Shares outstanding | 701.70m |
Free float | 83.13m |
P/E (TTM) | -- |
Market cap | 2.52bn USD |
EPS (TTM) | -1.54 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼